Minerva Neurosciences (NERV) Phase 3 Trial of Roluperidone for Treatment of Negative Symptoms in Schizophrenia Did Not Meet Its Primary and Key Secondary Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: NERV) | Delayed: 2.30 -0.1 (4.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.40 | 52 Week High | $15.84 | |||
| Open | $2.37 | 52 Week Low | $3.45 | |||
| Day High | $2.65 | P/E | N/A | |||
| Day Low | $2.25 | EPS | $0.00 | |||
| Volume | 88,015 | |||||
